Skip to main content
Premium Trial:

Request an Annual Quote

Edward Hurwitz, Brent Kreider, and Frank Witney


Edward Hurwitz, a venture partner of Alta Partners, has joined the board of directors of Mountain View, Calif.-based Aclara Biosciences. From 1997 to 2001, he was senior vice president and CFO of Affymetrix. Hurwitz holds JD and MBA degrees from the University of California, Berkeley, and a BA in molecular biology from Cornell University.

Brent Kreider has become senior vice president of cell-based microarray company Akceli in Cambridge, Mass. Kreider joins the company from Lexington, Mass.-based Phylos, where he was vice president of biological research. Prior to that, Kreider was a cell biologist and associate director at Human Genome Sciences. He holds a BS in microbiology from Penn State University and a PhD in molecular/microbiology from the University of Pennsylvania.

Frank Witney has become CEO of microarray startup GenoSpectra in Fremont, Calif., joining the company from PerkinElmer Life Sciences, where he was president. Prior to that, he served as president and COO of Packard BioScience. Previously, he was group operations manager of the life science group at Bio-Rad Laboratories. Witney holds a doctorate in molecular and cell biology from Indiana University.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.